A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 versus Standard of Care as first-line treatment of advanced or metastatic Non-Small Cell Lung Cancer with HER2- Mutations
Non-Small Cell Lung Cancer With HER2- Mutations
DRUG: SHR-A1811|DRUG: Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Progression-free survival (PFS) based on blinded independent central review (BICR), Defined as time from randomization until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), Until progression, assessed up to approximately 2 years
Overall Survival (OS), Defined as time from randomization until the date of death due to any cause, Until death, assessed up to approximately 3 years|Progression Free Survival (PFS) by investigator assessment, Defined as time from randomization until progression per RECIST 1.1 as assessed by the investigator, Until progression, assessed up to approximately 2 years|Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, until to 90 days after the last dose，assessed up to approximately 3 years
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 versus Standard of Care as first-line treatment of advanced or metastatic Non-Small Cell Lung Cancer with HER2- Mutations